Answers are grounded in this paper and cite their sources.
Autologous CAR T-cells achieve disease negativity in young patients, suggesting a promising treatment avenue.
Autologous second-generation CD7-directed CAR T-cells, expressing an anti-CD7 protein expression blocker to prevent self-killing fratricide, were infused in three pediatric/young adult patients with relapsed/refractory CD7+ acute myeloid leukemia resulting in measurable residual disease negativity. The safety profile was favorable.
No takes yet. Share an insight, caveat, or question.
Becilli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: